Connect with others who understand.

  • Learn from expert-reviewed resources
  • Real advice from people who’ve been there
  • People who understand what you’re going through
Sign up Log in
Personal Assistant What is This Site Help Center Crisis
Powered By
Myeloma Treatments/Myeloma Treatments

Gene-Based Therapy May Thwart a Tough Blood Cancer

Written by MyMyelomaTeam
Posted on December 20, 2018


By Dennis Thompson, HealthDay Reporter

MONDAY, June 5, 2017 (HealthDay News) -- Genetically tuning a person's own immune cells to target cancer appears to provide long-lasting protection against a blood cancer called multiple myeloma, an early trial from China shows.

The treatment, called CAR T-cell therapy, caused 33 out of 35 patients with recurring multiple myeloma to either enter full remission or experience a significant reduction in their cancer.
The results are "impressive," said Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society.

"These are patients who have had prior treatment and had their disease return, and 100 percent of the patients are reported to have had some form of meaningful response to these cells that were administered," Lichtenfeld said.

The new therapy is custom-made for each patient. Doctors collect the patient's own T-cells -- one of the immune system's main cell types -- and genetically reprogram them to target and attack abnormal multiple myeloma cells.

Lead researcher Dr. Wanhong Zhao likened the processto fitting immune cells with a GPS that steers them to cancer cells -- making them into professional killers that never miss their target.

Zhao is associate director of hematology at the Second Affiliated Hospital of Xi'an Jiaotong University in Xi'an, China.

CAR T-cell therapy is promising because the genetically altered T-cells are expected to roost in a person's body, multiplying and providing long-term protection, Lichtenfeld said.

"The theory is they should attack the tumor and continue to grow to become a long-term monitoring and treatment system," Lichtenfeld said. "It's not a one-shot deal."

The technology represents the next step forward in immunotherapy for cancer, said Dr. Michael Sabel, chief of surgical oncology at the University of Michigan.

"Immunotherapy is now really providing hope to a lot of patients with cancers that were not really responding to our standard chemotherapies," Sabel said.

CAR T-cell therapy previously has been used to treat lymphoma and lymphocytic leukemia, Lichtenfeld said.

Zhao and his colleagues decided to try the therapy to treat multiple myeloma. They re-engineered the patients' T-cells and then reintroduced them to the body in three infusions performed within one week.

Multiplemyeloma is a cancer that occurs in plasma cells, which are mainly found in bone marrow and produce antibodies to fight infections. About 30,300 people will likely be diagnosed with multiple myeloma this year in the United States, researchers said in background notes.

"Multiplemyeloma is a disease that historically was fatal in the course of a couple of years," Lichtenfeld said. During the past two decades, new breakthroughs have extended survival out 10 to 15 years in some patients, he noted.

To date, 19 of the first 35 Chinese patients have been followed for more than four months, researchers report.

Fourteen of those 19 patients have reached the highest level of remission, researchers report. There hasn't been a relapse among any of these patients, including five followed for more than a year.

"That's as far as you can go in terms of driving down the amount of tumor that's in the body," Lichtenfeld said.

Out of the remaining five patients, one experienced a partial response and four a very good response, researchers said.

However, about 85 percent of the patients experienced cytokine release syndrome (CRS), a potentially dangerous side effect of CAR T-cell therapy.

Symptoms of cytokine release syndrome can include fever, low blood pressure, difficulty breathing, and impaired organ function, the researchers said. However, most of the patients experienced only transient symptoms, and "now we have drugs to treat it," Lichtenfeld said.

History suggests the therapy will cost a lot if it receives approval, Lichtenfeld said. However, prior to approval, much more research will be needed, he added.

The Chinese research team plans to enroll a total of 100 patients in this clinical trial at four hospitals in China. They also plan a similar clinical trial in the United States this year, Zhao said.

The study was funded by Nanjing Legend Biotech Co., the Chinese firm developing the technology.

Note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate.

SOURCES: Len Lichtenfeld, M.D., deputy chief medical officer, American Cancer Society; Wanhong Zhao, M.D., Ph.D., associate director, hematology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China; Michael Sabel, M.D., chief, surgical oncology, University of Michigan; June 5, 2017, presentation, American Society of Clinical Oncology meeting, Chicago

Copyright © 2017 All rights reserved.
What do you think about gene-therapy treatment?
Share in the comments below or directly on MyMyelomaTeam.
All updates must be accompanied by text or a picture.

A MyMyelomaTeam Member

My doctor mentioned the CAR T-Cell Therapy trials to me. Very excited about the possibilities! At age 39, it would give my children new hope for keeping their mom around and I sure would love to help… read more

We'd love to hear from you! Please share your name and email to post and read comments.

You'll also get the latest articles directly to your inbox.

Subscriber Photo Subscriber Photo Subscriber Photo
52,351 members
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service.
Privacy Policy • Terms of Use
All updates must be accompanied by text or a picture.

Subscribe now to ask your question, get answers, and stay up to date on the latest articles.

Get updates directly to your inbox.

Subscriber Photo Subscriber Photo Subscriber Photo
52,351 members
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service.
Privacy Policy • Terms of Use

Related

Types Topics Multiple Myeloma Relapsed Myeloma News View All
Stem Cell Transplant for Multiple Myeloma: Life Expectancy, Recovery, and More
A hematopoietic stem cell transplant is a type of treatment used for people with multiple myeloma...
Stem Cell Transplant for Multiple Myeloma: Life Expectancy, Recovery, and More
A hematopoietic stem cell transplant is a type of treatment used for people with multiple myeloma...
Understanding Serum Protein Electrophoresis (SPEP) for Multiple Myeloma
A variety of tests play a role in diagnosing multiple myeloma, including serum protein electropho...
Understanding Serum Protein Electrophoresis (SPEP) for Multiple Myeloma
A variety of tests play a role in diagnosing multiple myeloma, including serum protein electropho...
Back Pain and Myeloma: What It Feels Like
Back pain is a common and challenging symptom of myeloma and is often one of the first symptoms t...
Back Pain and Myeloma: What It Feels Like
Back pain is a common and challenging symptom of myeloma and is often one of the first symptoms t...

Thank you for subscribing!

Become a member to get even more

See answer
See answer